This investigator-sponsored trial explores the combination of Venetoclax and Selinexor in patients with high-risk hematologic malignancies, specifically targeting Diffuse Large B-cell Lymphoma (DLBCL) and Acute Myeloid Leukemia (AML). The combination therapy aims to address unmet medical needs in refractory or relapsed cases, potentially enhancing treatment options in a competitive oncology market. Given the increasing prevalence of hematologic malignancies and the limitations of current therapies, successful outcomes could position this combination as a viable treatment alternative, influencing market dynamics and attracting interest from larger pharmaceutical entities. The collaboration with Karyopharm Therapeutics and AbbVie may also indicate strategic partnerships that could enhance commercialization efforts.